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Abstract 
 
With the rise of the HIV/AIDS epidemic in the past thirty years, people of all ages, 
infants to elderly alike, all over the world, suffer from its adverse effects. Even an unborn 
baby in-utero can contract this virulent infection by means of mother-to-child 
transmission (MTCT) (Sweeney, 2005). Infants and children diseased in this way 
comprise 90% of the estimated 800,000 new cases of HIV in children seen each year, but 
the region hit hardest, however, is Sub-Saharan Africa, with the country of Uganda 
historically having the highest incident rate for a time (Stringer, E.M., et al. 2008). 
Therefore, the purpose of this paper is to learn more about the prevention of MTCT in 
order to attain a better understanding of what is being done in this arena to impede HIV 
progression, to discover gaps in HIV/AIDS research and application, and to discern new 
and appropriate avenues in which a broader spectrum of people could contribute to the 
prevention of MTCT.  
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Prevention of Mother-to-child Transmission (PMTCT) of 
 
HIV in the Sub-Saharan Africa Region with a Focus on Uganda  
 No region of the world is exempt from the ravenous effects that the human 
immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) inflicts 
upon people of all ages at one level or another. It is an epidemic brought on by personal 
human behavior (UNAIDS, 2004). Unlike some diseases that have been around for 
centuries, HIV/AIDS is a more recent reality. In the year 1981, clinicians identified it as a 
new immunodeficiency syndrome found in homosexual men referred to as “gay-related 
immunodeficiency syndrome” or GRIDS (Sweeney, 2005). The incidence of this 
syndrome was steadily increasing, and it was eventually termed AIDS (Sweeney). It did 
not take long for people to realize that this disease could also be heterosexually 
transmitted when the virus was found passed to women as well (Gross, 2004).  
Although a debatable issue, Kasensero, located in Uganda’s Rakai district, is 
considered by some to be the site of the AIDS origination (Shoumatoff, 1988). The 
people of Uganda do not regard this disease as their own (Shoumatoff). However, 
evidence of AIDS in Uganda traces back to 1972 in the northwestern region, the 
homeland of Idi Amin in the Nile Province (Shoumatoff). Robert Gallo, who was a 
renowned AIDS researcher in America, noted that, “All the scientific signposts point to 
an origin in Africa, somewhere around the region of Lake Victoria” (cited in Shoumatoff, 
p. 132).    
As knowledge of this fatal condition has increased in the last three or four 
decades, so have the number of people who have been infected with the virus. Despite the 
fact that the entire world experiences the effects of HIV, the region of Sub-Saharan 
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Africa has been more negatively affected by the virus than any other location (Sweeney, 
2005). There has been a shift from men to women in the percentages of those infected 
with HIV. The Global Program of the World Health Organization’s executive director 
announced it to the world back in 1993 that 50% of the new infections consisted of 
women and that most of the cases in Sub-Saharan Africa involved women (Gross, 2004).  
More than a decade ago, in-depth scientific research was published in the Journal 
of Virology on HIV-1 infection of tissues and cells found on the upper and lower female 
reproductive tracts (Howell et al. 1997). From the Howell et al. research study, it was 
discovered that the tissues and cells of the female reproductive tract are vulnerable to 
being infected with HIV, and once those cells have been exposed to the virus, it only 
takes a minimum of 60 minutes for the infection to take hold (Howell, et al. 1997). The 
research also supported that varying levels of hormones may play a role in the production 
of the virus and its ability to infect the body because an increase in the recovery of the 
virus was observed in cervical ectopy, while using oral contraceptives, and pregnancy 
(Howell, et al. 1997). Even though these findings are from years ago, they have helped to 
set a framework for preventing transmission of HIV (Howell, et al. 1997).  
As further research was performed and HIV/AIDS transmission was understood 
more, it was found that one of the three main modes of acquiring this virus is through 
perinatal transmission from the mother-to-child (MTCT) (Sweeney, 2005). In order to 
prevent the further spread of this virus, much work and research is still required so that 
the unborn babies of mothers who are inflicted with HIV may be protected. 
 The issue of MTCT is of great concern and demands attention because more 
recent records from 2006 show that approximately 2.3 million children under the age of 
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15 suffered from transfer of HIV, and of the 39.5 million people living with HIV around 
the world, approximately 17.7 million of them were women (Guidance, 2007). A study 
performed in Nigeria on leaders’ perceptions of mother-to-child transmission prevention 
alleged that over half of a million children every year acquire the virus, but it is through 
mother-to-child transmission in which 90% of those children get it (Arulogun, Adewole, 
Olayinka-Alli, & Adesine, 2007). This means over 1400 young children and teenagers 
not yet 15 years old from impoverished areas are afflicted with this virus daily 
(Guidance). Updates from the World Health Organization (WHO) continue to support 
that most of these cases are found in Sub-Saharan Africa due to the fact that among 
pregnant women living in those countries there is a high prevalence for HIV, and it is a 
region in which the health-care infrastructure is under resourced (Stringer, E.M., et al. 
2008). Without effective prevention measures, a large number of these infants and 
children, more than 50%, will not live to see the day they turn two years old (Guidance).  
Of the 90% or more of the new cases seen in infants and young children that 
occur through mother-to-child transmission, there are three areas or routes by which these 
children are at risk of contracting the virus. According to researchers that make up the 
Interagency Task Team (IATT) on Prevention of Mother-to-Child Transmission 
(PMTCT), these include the following: during the antenatal time, or pregnancy, during 
the birth, or through breastfeeding (Guidance, 2007). An even more recent piece of 
literature from the Bulletin of the World Health Organization discussing the effectiveness 
of MTCT prevention in countries of low income identified from a plethora of studies 
some significant reoccurring risk factors. The following have been referred to as the most 
important when regarding perinatal transmission: vaginal birth, breastfeeding, a low 
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count of CD4+ lymphocyte cells in the mother, and a high HIV viral load in the mother’s 
plasma (Stringer, E.M., et al. 2008). Whatever the causes may be, if nothing is done to 
prevent this infestation, then anywhere between 20% and 45% of those children born to 
HIV-diseased mothers could contract the virus (Guidance). Research gathered by the 
IATT estimates that breastfeeding could be responsible for 5-20%, labor and delivery 10-
20%, and the time during the pregnancy, 5-10%, of transmitting HIV (Guidance). Earlier 
research from a decade ago suggested that breastfeeding was responsible for half of the 
mother-to-child transmissions, while pregnancy and birth caused the other half of 
transmissions (Weinreich, 2003).  
Overview of the Disease Process 
With all of these alarming statistics and specific terms being thrown around, terms 
such as “viral load” or “CD4 levels,” a basic overview of the disease and why it is such a 
virulent infection is necessitated. This human immunodeficiency virus (HIV) can 
eventually develop into what has been termed AIDS which stands for “acquired 
immunodeficiency syndrome,” as noted above. The passing of the virus has four main 
modes of transfer, two of which are horizontal modes and two that are vertical 
(Hockenberry, 2005). The former two include exposure to blood and sexual contact, the 
latter, childbirth and breastfeeding (Gallant, 2009). The term vertical refers to the passing 
of HIV perinatally from the mother to the infant (Hockenberry). Transmission through 
mosquitoes or other insects is not a mode of transfer (Sweeney, 2005). Also, the 
occurrence of viral spread from infected individuals to uninfected individuals by means 
of casual contact has not been supported by evidence (Hockenberry).  
  Mother-to-child transmission 8 
A key concept about this virus is that HIV is a retrovirus (Sweeney, 2005). Such 
is the nature of all viruses HIV cannot duplicate if it is not inside of a living cell 
(Bradley-Springer, Shaw, & Lewis, 2007). A retrovirus produces enzymes that allow 
RNA to manufacture DNA through a reverse transcription process. RNA is the 
retrovirus’ own genetic material that has the capability of becoming DNA. Normally, 
DNA turns into RNA through the process of transcription, but HIV is called a retrovirus 
because it does just the opposite (Gallant, 2009). Once the virus has infected the body, it 
uses reverse transcriptase, the enzyme, to convert the RNA into the DNA. This new 
DNA, which used to be RNA, is now able to enter human cell DNA (Gallant). This entry 
allows for more virus to be formed and more healthy cells to potentially be affected. It is 
as if the virus is disguised in human DNA but now wears an ominous mask. It can also lie 
quiet for years, in a latent phase, like a dangerous reservoir or volcano waiting to erupt 
(Gallant).  A reservoir cell can survive as long as a human while it houses the infection, 
which allows the virus to be latent (Gallant).  An example of a reservoir would be a long-
lasting resting CD4 cell. The inside of the cell is a nest for viral DNA. Because 
replication cannot occur, antiretroviral therapy will prove ineffective for this sick cell 
(Gallant). The phrase “viral load” refers to the quantity of HIV components found within 
the blood plasma (Bradley-Springer, et al.).  
 The significance of this retrovirus attacking the CD4+ cells is that the CD4+ cell 
is a kind of T lymphocyte, more specifically a T lymphocyte sub-category (Hockenberry, 
2005). It is the job of the lymphocytes to take charge over the response of the immune 
system when infection invades the body (Sweeney, 2005). The lymphocytes are what 
help to keep a normally functioning healthy body from illness. When HIV strikes 
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however, these crucial lymphocytes are now becoming poisoned, so to speak, with the 
virus and cannot effectively perform their life-sustaining responsibilities. This is because 
the virus hijacks CD4+ lymphocyte’s mechanics so that viral duplication can occur. This 
leaves the CD4+ cell unable to function properly (Hockenberry). It is a vicious cycle, for 
when the RNA of HIV has used reverse transcriptase to become DNA, the virus 
proliferates (Sweeney).  As the virus continues to spread, the levels of healthy CD4+ T 
lymphocytes significantly decline, and as a result, the immune system deteriorates.  The 
body, under normal circumstances, has approximately 800-1000 CD4 cells/uL. An HIV-
infected person transitions into having AIDS when their CD4+ T lymphocyte count falls 
below 200 cells/uL (Hockenberry). This is why people with HIV acquire other forms of 
infection, such as pneumocystis carinii, which is a type of pneumonia that is hallmark in 
a patient with HIV. Susceptibility to Kaposi sarcoma, a form of malignant skin cancer 
that negatively impacts the endothelial cells of blood vessels is also prevalent (Sweeney). 
It is fascinating that this type of sarcoma has been noted as mainly a cancer of Africa that 
was seldom seen in the West (Shoumatoff, 1988). It was apparently Kaposi sarcoma that 
was a significant cause of death in some of the earlier AIDS incidents seen in Europeans 
and Americans; they were vexed by the seemingly “African” pattern of the disease 
process (Shoumatoff).  
 These conditions, along with a long list of others, are referred to as opportunistic 
infections. Because the immune system is so compromised due to the sick CD4 cells, the 
body is incapable of controlling and battling off these non-rapacious diseases (Sweeney, 
2005).  The Centers for Disease Control (CDC) established a defining classification grid 
for people with the infection that became effective in 1993 on January first. Three 
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categories were designed based on the levels of CD4 cells per microliter (ul) of blood 
(Sweeney). Category 1: >500 cells/uL, category 2: 200-400 cells/uL, and category 3: 
<200 cells/uL (Sweeney, p. 431). See Table 1 below. 
Table 1: CD4+ Cell 
Categories 
Clinical Categories 
Key to abbreviations: 
CDC = U.S. Centers for 
Disease Control and 
Prevention 
PGL = persistent 
generalized 
lymphadenopathy. 
A  
Asymptomatic, 
Acute HIV, or PGL 
B  
Symptomatic 
Conditions, not A 
or C 
C  
AIDS-Indicator 
Conditions 
(1) ≥500 cells/µL A1 B1 C1 
(2) 200-499 cells/µL A2 B2 C2 
(3) <200 cells/µL A3 B3 C3 
Category B Symptomatic Conditions parameters are identified in Table 2 
Category C AIDS-Indicator Conditions parameters are identified in Table 3 
Note: Re-designed from the CDC “1993 Revised Classification System for HIV Infection and Expanded 
Surveillance Case Definition for AIDS Among Adolescents and Adults,” by K.G. Castro & J.W. Curran, 
1992, MMWR and (HIV Classification: CDC & WHO Staging Systems, (2006) AETC National Resource Center, 
2009) 
 
 
Table 2: Symptomatic Conditions included in Category B: CDC Classification 
System in Adolescents and Adults  
• Bacillary angiomatosis 
• Candidiasis, oropharyngeal (thrush)  
• Candidiasis, vulvovaginal; persistent, frequent, or poorly responsive to therapy  
• Cervical dysplasia (moderate or severe)/cervical carcinoma in situ  
• Constitutional symptoms, such as fever (38.5 C) or diarrhea lasting greater than 1 month  
• Hairy leukoplakia, oral  
• Herpes zoster (shingles), involving at least two distinct episodes or more than one dermatome  
• Idiopathic thrombocytopenic purpura  
• Listeriosis 
• Pelvic inflammatory disease, particularly if complicated by tubo-ovarian abscess  
• Peripheral neuropathy 
 
Note: Table 2 & 3 Re-created from “1993 Revised Classification System for HIV Infection and Expanded 
Surveillance Case Definition for AIDS Among Adolescents and Adults,” by K.G. Castro & J.W. Curran, 
1992, MMWR Copyright 1993 Centers for Disease Control 
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Table 3: Conditions included in the 1993 AIDS surveillance case definition 
• Candidiasis of bronchi, trachea, or lungs  
• Candidiasis, esophageal  
• Cervical cancer, invasive *  
• Coccidioidomycosis, disseminated or extrapulmonary  
• Cryptococcosis, extrapulmonary  
• Cryptosporidiosis, chronic intestinal (greater than 1 month's duration)  
• Cytomegalovirus disease (other than liver, spleen, or nodes)  
• Cytomegalovirus retinitis (with loss of vision)  
• Encephalopathy, HIV-related  
• Herpes simplex: chronic ulcer(s) (greater than 1 month's duration); or bronchitis, 
pneumonitis, or esophagitis  
• Histoplasmosis, disseminated or extrapulmonary  
• Isosporiasis, chronic intestinal (greater than 1 month's duration)  
• Kaposi's sarcoma  
• Lymphoma, Burkitt's (or equivalent term)  
• Lymphoma, immunoblastic (or equivalent term)  
• Lymphoma, primary, of brain  
• Mycobacterium avium complex or M. kansasii, disseminated or extrapulmonary  
• Mycobacterium tuberculosis, any site (pulmonary * or extrapulmonary)  
• Mycobacterium, other species or unidentified species, disseminated or extrapulmonary  
• Pneumocystis carinii pneumonia  
• Pneumonia, recurrent *  
• Progressive multifocal leukoencephalopathy  
• Salmonella septicemia, recurrent  
• Toxoplasmosis of brain  
• Wasting syndrome due to HIV  
• Added in the 1993 expansion of the AIDS surveillance case definition. 
Note: Table 2 & 3 Created From “1993 Revised Classification System for HIV Infection and Expanded 
Surveillance Case Definition for AIDS Among Adolescents and Adults,” by K.G. Castro & J.W. Curran, 
1992, MMWR Copyright 1993 Centers for Disease Control 
 
 
The three divided phases of this infection are also significant to note. It takes 
about 8-12 years for these phases to run their course (Sweeney, 2005). These include the 
following: the primary infection phase, chronic asymptomatic or latency phase, and the 
overt AIDS phase (Sweeney). In the primary infection phase, a victim of the virus may 
experience symptoms such as fever and rash, the two most commonly seen, two to four 
weeks after they have been exposed (Sweeney).  The symptoms could last for a few days 
to a couple of weeks (Sweeney). Other symptoms of this acute phase include the 
following: fatigue, myalgias, sore throat, night sweats, gastrointestinal complications, 
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lymphadenopathy, maculopapular rash, and headache. This phase resembles a 
mononucleosis-like syndrome (Sweeney).  It is in this first phase when patients should 
receive treatment so as to decrease the existing CD4+ memory cells that have been 
infested by the virus (Sweeney). From the primary phase, the course of the disease goes 
into the latent phase, in which the virus may stay quiet and demonstrate no symptoms or 
signs of disease. The average latent period is ten years (Sweeney).  Despite its illusive 
existence, the CD4 levels have then plummeted to 200u/L or lower, and once these levels 
hit 200, the patient is deemed to be in the third phase of HIV, which then becomes “overt 
AIDS,” and signs and symptoms seen through these opportunistic infections become 
more and more apparent, to the point where they are quite distinguishable and 
unavoidable (Sweeney).  Death is impending in two to three years if left untreated by 
anti-retroviral therapy (Sweeney).  
Interventions Overview 
The goal of reviewing literature pertaining to the prevention of MTCT is to 
research methods or practices that are effective in making the PMTCT successful. It is 
important to assess the gaps or loopholes that do not allow for prevention to take effect. If 
the virus is transmitted through breastfeeding, pregnancy, and labor and delivery, then 
reviewing research that focuses on how the transmission occurs in those areas is 
important, as well as interventions that have shown to either be helpful or ineffective.  
The Weekly Epidemiological Record suggested that there has been an increase in 
interventions to halt vertical transmission from happening between the mother and child 
(May, 2007). The Record supports the belief that if these interventions are implented 
between the mother and child, then a significant number of infants birthed from mothers 
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who have HIV will not end up contracting the virus perinatally (Weekly, 2007). If safe 
delivery practices are utilized and antiretroviral therapy is incorporated to prevent the 
mother from transmitting the virus to the baby, and diagnosing the mother with HIV early 
on so prevention can be attempted, then these infants have a chance of escaping this 
deadly virus (Weekly). For a pregnant mother who carries her child to term, the risk of 
passing the virus to the infant can be reduced to approximately two percent if the child is 
delivered via cesarean section, and she is on medication that will lower the circulating 
virus in her blood (Bartlett & Finkbeiner, 2001).  
Advances in such implementations are crucial because if proper preventative 
measures are not taken infants could end up struggling to live life HIV-infected from 
birth. Because of the body’s phenomenal design and natural protection set in place, the 
placenta prevents the passage of the virus to the fetus. Nevertheless, this is not fully 
guaranteed because the placenta is vulnerable to failure if the following three conditions 
occur: the mother during the antenatal period acquires a parasitic, bacterial, or viral 
infection in the placenta, she herself gets the virus while pregnant, her viral load is high, 
or she is extremely immune compromised because her current case of AIDS is quite 
advanced (Campbell, 2005). The fetus is in a potential danger zone and not just during 
the antenatal time; the birthing process jeopardizes the infant’s safety. It has been noted 
that, if nothing is done to keep the infant from acquiring the virus via birth, then as many 
as 10 to 20 percent will get the infection (Campbell). As gruesome as it sounds, the child 
may access the virus during the delivery process by aspirating the mother’s HIV 
contaminated blood or secretions or through imbibing or sucking (Campbell). At least 
two other conditions have also been correlated with an increased risk of transmitting the 
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virus to the infant because exposure to maternal blood escalates. These would include 
acute chorioamnionitis and membrane rupture time interval. The former is the result of 
sexually transmitted infections as well as other forms of infections that were left 
untreated. The latter procedure is done to initiate or enhance labor. Finally, delivery 
tactics that are invasive and that heighten the infant’s interaction with maternal blood can 
also increase HIV transmission (Campbell). In light of cases such as these, a Caesarean 
section performed at 38 weeks is highly encouraged and preferable. However, in certain 
regions where HIV is rampant and healthcare interventions and resources are basically 
nonexistent, a C-section is asking too much. This is where intervention programs 
incorporating volunteer testing, transportation, funds, planning, availability of 
antiretroviral drugs, safe antenatal care, delivery, replacement feeding, and postnatal care 
campaigns are vital to infant survival for some of these families, as well as their mothers 
(Campbell).  
Since HIV can also be secreted in breast milk, practicing safe infant feeding 
methods is critical. Evidence-based research supports transmission of HIV through 
breastfeeding, particularly in the early weeks of life of the infant (Ross & Labbock, 
2004). When discussing how to avoid transmitting the virus, some experts strongly 
counsel against breastfeeding in a situation in which the mother is infected with HIV 
(Bartlett & Finkbeiner, 2001). The risk of HIV being transmitted through breast milk 
over a six to twelve month period is between 15% & 25%. Anti-retrovirals administered 
to both mother or child will likely reduce transmission; the exact reduction is not defined 
(Bartlett & Finkbeiner, 2001). Alternatives to breastfeeding might include infant formula, 
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utilizing the services of a lactating HIV negative woman within the community, or 
acquiring breast milk from a milk bank or a local co-op.  
In the United States breast milk is available through a plethora of banking and co-
op services. In these organizations, healthy women donate their milk to help care for 
children whose nutritional statues is hindered by the mother’s inability to breast-feed. 
The most exacting of these services is the National Milk Bank that requires certification 
for their milk product. To date, they are the strictest of the milk banks to ensure safety. 
For example, all of their donors are screened for HIV and hepatitis B and C and are DNA 
finger-printed to ensure that the donation matches the screened donor (National, 2008).  
While Bartlett & Finkbeiner (2001) are steadfast on their opposition to 
breastfeeding when HIV positive, clearly the expense and practicality of milk bank 
services in a developing nation setting would preclude this as an option. Even the 
expense of formula is beyond the means of most families in under-developed areas. 
Therefore, other authorities are more open to the breastfeeding option for HIV positive 
mothers.  
Ross & Labbok (2004) offer an important additional argument in consideration of 
breastfeeding versus artificial feeding. Infants depending entirely on artificial feeding 
may receive nutrition, but are deprived of the natural antibodies. Without the benefit of 
maternal antibodies the child’s risk of death is compounded. The risk-to-benefit ratio of 
acquiring HIV must be weighed to determine the value of artificial feedings versus 
breastfeeding. In their study of a region of high HIV prevalence, they concluded that an 
infant should not be given artificial feeding prior to six months of age (Ross & Labbok). 
During those early months, the feeding of natural breast milk should be initiated because 
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HIV-free survival increases by over three percent (Ross & Labbok). Their findings 
invalidate earlier studies (Miotti, et el., 1999; Taha, et al., 1998) alleging the risk of 
MTCT through breastfeeding is at its highest during those earlier months. The 
transmission risk continues as breastfeeding continues; some studies supported an 
increased risk of transfer with a longer duration of breastfeeding (Miotti, et el., 1999; 
Taha, et al., 1998). Increased parity greater than four and increased maternal age 
decreased the risk of transmission among HIV positive women (Miotti, et el., 1999). 
These findings are contradicted by a South African study, which found that exclusive 
breastfeeding might protect children from HIV infection while maintaining the benefits 
of breastfeeding (Coutsoudis, Pillay, Spooner, Kuhn, & Coovadia, 1999). Further study 
from South Africa found no excess risk of HIV infection for infants that were exclusively 
breastfed for three or more months (Coutsoudis, A. et al., 2001). Recent research from 
Tanzania found that the risk of MTCT in breast milk might be reduced if concentrations 
of n-6 polyunsaturated fatty acids including arachidonic acid were increased in breast 
milk. (Villamor, et al. 2007). Readily available maternal food sources for these 
compounds include fish, eggs, meat, and peanut oils may increase these essential fatty 
acids in breast milk (Calder, 2007).  
Preventing the transmission of this virus to the child is so essential because these 
babies do not respond in the same way immunologically as adults do to the attack of the 
HIV infection (Bartlett & Finkbeiner, 2001). As children grow, their bodies build up their 
immune systems to be able to attack foreign invaders or pathogens and produce 
antibodies to fight them off when they return, but if a child is born with an 
immunodeficiency virus and cannot be breastfed, then HIV will be hindering an immune 
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system that is not even fully developed, causing the infant to be in a weakened state that 
will lead to an impending death if interventions do not come to the aid of the child. The 
child is born with immunity, but a mother’s endogenous breast milk steeped with 
antibodies allows the infant to gain the essential natural passive immunity from the 
mother (Porth, 2005). 
The agencies collaborating on global improvement of the PMTCT of HIV note 
that decreasing the percentages that HIV is transmitted to the baby through breastfeeding, 
pregnancy, labor and delivery can be done by implementing an evidence-based 
interventions package (Guidance, 2007). In the majority of countries that have a higher 
income, this package serves as the standard (Guidance). This literature published six 
years after Bartlett and Finkbeiner’s alleges that the risk factor of PMTCT is now less 
than two percent. In areas where the package is implemented, the results show very few 
new HIV cases in children (Guidance). The concern that the WHO has for developing 
countries such as those in Sub-Saharan Africa is that the resources are limited (Stringer, 
E.M., et al. 2008). The transmission risks do not change, but the implementation of 
effective prophylaxis is universally lacking including availability of preliminary antenatal 
care, Caesarean-sections that are elective, anti-retroviral (ARV) regimens, and finally 
substantial substitutes to breastfeeding (Stringer, E.M., et al. 2008). Despite this 
pessimistic fact, data from the World Health Organization recorded from the years 2003-
2007 demonstrates in Chart 1 below an example in which global intervention has not 
been in vain as antiretroviral coverage in the Sub-Saharan region has clearly gone in the 
right direction.   
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Chart 1. Map Displaying ART Treatment in the sub-Saharan Region in the years 2003-07 
d 
Chart 1. Note: From HIV/AIDS Data and statistics. World Health Organization. Copyright WHO 2009  
Incorporating interventions by means of family planning and primary prevention 
offer more hope (Weinreich, 2003). Primary prevention means that women in their 
reproductive years should attempt to prevent themselves from getting the HIV infection 
in the first place, but that uncovers a whole other set of issues and complications 
(Weinreich). Family planning for women already infected with HIV can take advantage 
of contraceptive methods and seek counseling since they are already aware of their 
condition (Weinreich). There is still hope for prevention; all is not yet lost.  
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Since the arrival of the first drug used to treat HIV in 1987, a number of classes 
and drug types have been produced and are to be taken in combination with each other to 
counteract the many effects that this virus has on the body (Hockenberry, 2005). With 
these therapy regimens, the desired effect is to see a decline in the viral load, an incline in 
the healthy CD4+ T lymphocytes, and finally to impede the progression of opportunistic 
disorders and accompanying symptoms that are notorious of the HIV infection (Bradley-
Springer, et al., 2007).  
There are six categories of antiretroviral drugs. Table four below may be referred 
to for a clear depiction of what the job of each class is and examples of each category. 
Table 4: Six Categories of HIV Antiretroviral Drugs  
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Note. [Material used to create table from] Medical-Surgical Nursing: Assessment and Management Clinical 
Problems (7th ed.). (p. 257), by L. Bradley-Springer, C.A., Shaw, & S.L. Lewis, 2007, St. Louis, MO: 
Mosby, Inc.  
 
The first group is the nonnucleoside reverse transcriptase inhibitors (NNRTIs). 
These drugs, in combination with the reverse transcriptase enzyme, basically prevent the 
process necessary for the conversion of HIV RNA to HIV DNA to take place. (Bradley-
Anti-retroviral Drug 
Classes 
Description of Action Drug Examples 
Group 1: Non-
nucleoside reverse 
transcriptase inhibitors 
NNRTI  
These drugs, in combination 
with the reverse transcriptase 
enzyme, basically prevent the 
process necessary for the 
conversion of HIV RNA to 
HIV DNA to take place 
• Nevirapine (Viramune) 
• Delavirdine 
(Rescriptor) 
• Efavirenz (Sustiva)  
Group 2:  Nucleoside 
reverse transcriptase 
inhibitors 
NRTI 
This class of drugs interleaves 
a portion of DNA into the HIV 
DNA chain that is in the 
process of developing. The 
newly placed DNA halts the 
progression of the HIV DNA, 
rendering it an unfinished 
chain 
• Zidovudine (AZT, 
ZDV, Retrovir 
• Stavudine (d4T, Zerit) 
• Lamivudine (3TC, 
Epivir), Abacavir 
(Ziagen) 
Group 3: Nucleotide 
reverse transcriptase 
inhibitors 
NtRI 
These drugs prohibit the 
activity of reverse 
transcriptase 
• Tenofovir DF (Viread)  
• Truvada (tenofovir and 
emtricitabine 
combination) 
Group 4: Protease 
Inhibitors 
PI 
The PIs thwart the work of the 
protease enzyme so that it 
cannot compartmentalize the 
HIV proteins into appropriate 
sections necessary for the 
workable virions to amass and 
sprout out from the membrane 
of the cell 
 
• Saquinavir (Fortovase, 
Invirase)  
• Indinavir(Crixivan) 
• Ritonavir (Norvir)  
• Nelfinavir (Viracept) 
• Amprenavir 
(Agenerase) 
Group 5: Entry Inhibitor This drug type is given to not 
allow passage of HIV into the 
cells by halting the binding of 
the virus to the desired CD4+ 
receptor site. By stopping this 
entry, internal duplication 
within the cell is prevented 
• Enfuvirtide (Fuzeon) 
Group 6: Integrase 
Inhibitors  
These drugs inhibit the 
process known as integration 
that has to occur for HIV’s 
DNA to become part of the 
CD4 cell’s DNA 
(aidsmeds.com) 
• Raltegravir 
• Elvitegravir 
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Springer, Shaw, & Lewis, 2007). The second group known as the nucleoside reverse 
transcriptase inhibitors (NRTIs), interleaves a portion of DNA into the HIV DNA chain 
that is in the process of developing. The newly placed DNA halts the progression of the 
HIV DNA, rendering it an unfinished chain (Bradley-Springer, et al.). The nucleotide 
reverse transcriptase inhibitors (NtRI) prohibit the activity of reverse transcriptase 
(Bradley-Springer, et al.). Despite their individual specific modes of interference, these 
three classes together halt the action of reverse transcriptase. The next group, the protease 
inhibitors (PIs) interrupt the work of the protease enzyme. More specifically, the PIs 
thwart the work of the protease enzyme so that it cannot compartmentalize the HIV 
proteins into appropriate sections necessary for the workable virions to amass and sprout 
out from the membrane of the cell (Bradley-Springer, et al.). The entry inhibitor drug is 
given to not allow passage of HIV into the cells by halting the binding of the virus to the 
desired CD4+ receptor site. By stopping this entry, internal duplication within the cell is 
prevented (Bradley-Springer, et al.). Finally, the integrase inhibitor drugs attempt to halt 
the process known as integration that has to occur for HIV’s DNA to become part of the 
CD4 cell’s DNA (Integrase, 2007). It is crucial that these anti-retrovirals are taken in 
combination with each other, such as an HIV drug cocktail, to impede viral progression 
as well as prevent potential viral mutations that can occur with not following an ART 
regimen. Also, the virus can become resistant and unresponsive to treatment (Bradley-
Springer, et al.). In other words, one region of a country may not respond to a certain 
drug due to the corresponding resistance that has arisen in the virus in that particular area. 
Sensitivity data must be researched and considered to determine the most affective drug 
treatment combinations.  
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 Study trials performed in countries such as Thailand and Cote d’Ivoire using 
short-course zidovudine (ZDV) and in Uganda using single-dose nevirapine showed 
hopeful results that simple, short course ARV regimens work. It also showed though that 
the more suppressive regimens that are used for a longer time period do work better 
(Stringer, E.M., et al. 2008). Even for countries that are resource-constrained, it is 
encouraging that simple, short-course zidovudine coupled with single-dose nevirapine 
used prophylactically (a cheaper antiretroviral regimen), has shown to be effective in 
significantly decreasing the risk of transmission to a fetus in utero and intra-partum 
(Guidance, 2007). 
Even though this regimen is less expensive than others, for some countries drug 
cost is still an issue. Records from Uganda show that in the year 2004, it took US $-
180.00 per person for the year as the average cost coverage for the first-line regimen, 
laboratory tests, and training. The first-line regimen included the zidovudine (stavudine), 
lamivudine, and nevirapine (or efavirenz) (Uganda, 2005). Even though that is a small 
sum for a year for high-income countries, there is a shortage of human resources as well 
as low salaries, a ban on hiring, and decreased incentive in the public sector (Uganda). 
The district and sub-district levels are at a disadvantage because accessibility to 
antiretroviral therapy is quite limited (Uganda). 
Donations of Nevirapine by the Boehringer/Ingelheim manufacturer have been 
given at no charge since 2001 to developing countries, which effectively decreases 
MTCT (Weinreich, 2003). A study done in Uganda with the use of Nevirapine displayed 
a reduction in vertical transmission by 50%; both the mother and child received the drug, 
the mother during delivery and the infant after birth (Weinreich). Also, the children that 
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received nevirapine (NVP) over zidovudine (AZT) were at a much lower risk of 
acquiring the infection (Weinreich). An attempt made by the Division of HIV/AIDS 
Prevention to decrease MTCT by the use of zidovudine therapy in the nineties was 
written up in the Morbidity and Mortality Weekly Report (MMWR) seven years ago, 
stating that ZDV was effective in lowering MTCT and was eagerly accepted in clinical 
practice (Wortley, Lindegren, & Fleming, 2001). More recent evidence-based findings 
support that nevirapine has shown to be more efficacious than zidovudine in certain 
circumstances, and the literature does support NVP as a more favorable drug in some 
areas than ZDV. This observation though is based on reviewed literature from a limited 
number of studies and research that has previously been performed.  
There has been concern over the issue of nevirapine toxicity due to extensive use 
of this drug. The Stringer, J.S., Sinkala, Rouse, Goldenberg, & Vermund research study 
aspired to weigh drug toxicity versus benefit. This uneasiness had halted the use of 
nevirapine as prophylactic therapy for perinatal HIV transmission because of it (2002). 
Results of this study also supported NVP as a more effective drug than ZDV in that it 
showed NVP would prevent more deaths than ZDV would, and they concluded that there 
should not be a delay in the utilization of NVP on the field, despite the arisen qualms 
regarding its toxicity (Stringer, J.S., et al. 2002). However, field implementation also 
showed that NVP resistance is a problem due to viral strains (Stringer, J.S., et al. 2002). It 
is widely used as a first-line drug, thus some kind of intervention is necessary, and it 
needs to be done quickly (Weinreich, 2003). The World Health Organization (WHO) 
Technical Consultation supports the conclusion from the Stringer, J.S., et al. 2002 study 
in noting that the benefit that drugs such as ZDV, NVP, and lamivudine (3TC) have on 
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decreasing MTCT of HIV significantly countervails for any of the possible consequences 
that exposure to these drugs would have on the individuals (Technical, 2000).  
A study was published in 2007 that judged the operational effectiveness of single-
dose nevirapine in preventing mother-to-child transmission of HIV presented with similar 
results, concluding that in the operational setting, early transmission of HIV can be 
reduced when single-dose nevirapine is administered to both the infant and the mother 
(Colvin, et al., 2007). Even though nevirapine has shown to be effective, the study was 
aimed at evaluating the effectiveness of the program, which was intended to prevent 
mother-to-child transmission. The researchers noted that in order for MTCT of HIV to be 
lowered, many important steps must be incorporated. For example, a care continuum 
must be present so that the acceptance and availability of pre-test counseling and HIV 
testing is monitored, women revisit in order to review the results, and follow-up care after 
the child is born is accessible (Colvin, et al., 2007). From the study, however, there was a 
deficit in a number of these critical factors seen in multiple African countries. This is 
attributed to the fact that PMTCT programs like this are being offered to health systems 
that are, as Colvin, et al., 2007 describes, “overburdened” (p. 466). This makes programs 
with good intentions ineffective to floundering health systems (Colvin et al., 2007).  
Therefore, the study concluded that there is a need for scaling-up antiretroviral regimens 
(Colvin et al., 2007). Similar to the study done in Uganda, nevirapine also showed to be 
more efficacious than zidovudine in the Colvin et al. research when looking at the 
percentage of infants found to be HIV positive at age 5-8 weeks (2007). The results of 
zidovudine therapy revealed 20.0% of infected infants, but the infection rate using 
nevirapine was only11.8% (Colvin et al., 2007). Finally, it was noted for this particular 
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study that a high viral load of HIV-1 RNA in the mother was the most significant risk 
factor for transmission; this fact is supported by numerous multivariate analyses in 
women not receiving prophylaxis through antiretroviral therapy or in those taking 
antiretrovirals (Colvin et al., 2007). Analysis has repeatedly displayed that maternal HIV-
1 RNA levels represent the leading predictor of newly transmitted HIV or the risk of 
acquisition during labor and delivery for their infants (Colvin et al., 2007). It is quite 
logical that this is the case.  
The Arvold et al. research study on maternal HIV-1 DNA load and MTCT found 
the same to be true in that it notes the maternal HIV-1 RNA viral load (RNA-VL) was 
repeatedly shown to be the main risk factor. They mention that this includes antiretroviral 
prophylaxis when used for PMTCT (2007). The ART used in this study was zidovudine 
prophylaxis in the antenatal period, as well as for the infants after they were born (Arvold 
et al., 2007). The following chart provides another detailed visual that compares 
percentages of pregnant women who were getting drug therapy in Sub-Sahara Africa with 
other regions of the world from 2004-2007.  
 
 
 
 
 
 
 
 
 
 
 
 
Chart 2. Percentage of Seropositive Pregnant Women Covered by ART Therapy 
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Chart 2. Note: From HIV/AIDS Data and statistics. World Health Organization. Copyright WHO 2009  
 
Interventions and Gaps to Successful Prevention 
Antiretroviral regimens have shown to be a beneficial mode of slowing the 
HIV/AIDS epidemic, along with safer delivery practices, education on prevention, 
programs in PMTCT, and alternative feeding strategies, but HIV testing and volunteer 
counseling and testing (VCT) is another important venue used to decrease this MTCT. As 
helpful as antiretroviral therapy is, however, and manufacturers like 
Boehringer/Ingelheim have donated drugs to pregnant Ugandan women, it strongly 
necessitates further testing that many countries cannot afford (Weinreich, 2003). In light 
of this dilemma, only 1% of all pregnant African women receive VCT (Weinrich). 
Literature from the American Journal of Public Health supports this by noting that the 
necessary bridge to providing antiretroviral drug therapy will be through testing for HIV 
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during antenatal care (Bassett, 2002). The article agrees that African clinicians are unable 
to extend much help to those infected with HIV (Bassett). It mentions though that 
Uganda accepts its AIDS condition and has made strides in setting up voluntary testing 
centers for HIV (Bassett). It is important that a pregnant woman is aware of her infection 
status and that antenatal care can be given to both mothers and babies so they can not 
only survive, but be able to live healthy lives (Bassett).  
From a law and ethics perspective, an individual’s right to privacy and informed 
consent is certainly violated when HIV testing is something required (Davis & Cohen, 
1994). However, mandatory screening is a debatable issue. But the flip side is when an 
infant could be spared the infection if the mother’s status is revealed. A child can contract 
the virus during childbirth and through breastfeeding. If the proper preventative measures 
are taken, that child’s life has the potential to be free from HIV for life, despite its 
mother’s seropositive status (Post, 2003). Though they are not specifically mentioned, 
newborn HIV testing is a requirement in two states so far, based on material recorded 
from 2003 (Post). This clearly overrules the informed consent parameter because if the 
child is positive then the mother’s HIV condition is circuitously broadcasted (Post). No 
human individual wants to confront that he or she has been infected with AIDS. In many 
countries, if not the entire globe, there is a stigma attached to those who carry the sticker 
across their foreheads, and no one wants to be marginalized or judged based on their 
condition. Knowing whether one is positive for HIV or not is obviously a better option 
for everyone involved. It would not be an easy thing to face, but if screening were 
mandatory, especially if it impacted another being so closely, would not the benefit of 
preventing an infant from contracting the virus outweigh the shame that may accompany 
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accepting one’s state that can only be improved if properly acknowledged? Granted, as 
mentioned earlier, there are countries unlike the United States that do not look as kindly 
on or treat women with AIDS as they may do here. That fact is not to be belittled. Even 
in that case, if a woman were to conceive a child who was HIV positive and no 
interventions were acted upon, then eventually both could perish with no escape. It is a 
crisis that requires hope, a stigma change, and mostly prevention. With intervention such 
as screening, progress can be made.  
The long-term solution would be to have community education that would 
publicize and encourage volunteer counseling and testing, which would also incorporate 
men (Bassett, 2002). The use of VCT is necessary, but sometimes there are loopholes 
because women may not want to get tested, or if they do, they may not return for results. 
However, a short-term solution could involve offering the test with the right of the 
woman to “opt out” if she so desired (Bassett). This approach to testing supported by the 
Centers for Disease Control (CDC) is when a pregnant woman is informed that the HIV 
test is part of the group of standard prenatal tests provided to all women; she has the 
option to deter from having the test. If she does not request to decline from this HIV test, 
it will automatically be given (Reducing HIV, 2006). This way the woman does not feel 
forced into being tested by having the right to not take advantage of it.  
A study performed in urban Zimbabwe was recently done to understand the 
influence that routine antenatal HIV testing, using this “opt-out” approach, had on the 
PMTCT (Chandisarewa, et al., 2007). As the other trials have shown, simple 
antiretroviral therapy has proven to be efficacious in Sub-Saharan countries, but the 
uptake of these kinds of prevention or treatment drugs has been low in the clinics in 
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Zimbabwe. This is due mostly to HIV antenatal testing rates that are poor, but they 
believe that early detection of HIV in pregnant mothers through VCT to PMTCT is of 
utmost importance (Chandisarewa, et al., 2007). The study discussion notes that women 
in urban Zimbabwe perceived this routine testing to be a good option and they would be 
accepting of it, and thus positive statistics for PMTCT were increasing (Chandisarewa, et 
al., 2007). The study concluded that this kind of routine testing should be performed and 
executed in all Zimbabwe sites so that the impact that it has on PMTCT can be 
maximized to its fullest potential in the public health realm (Chandisarewa, et al., 2007).  
The “opt-out” approach has shown to be effective in the goal of PMTCT. Some 
support that mandatory HIV testing in areas where HIV is prominent has the possibility 
of decreasing MTCT as long as certain contingencies are in order. If so, then it is morally 
required for mandatory testing to be implemented (Schuklenk & Keinsmidt, 2007). This 
research advocates that pilot studies should be performed in certain areas of Africa to 
assess the ease at which it could be implemented as well as the potential ramifications, 
positive or negative, that mandatory testing might generate. The ethical and policy issues 
that accompany this approach make for a multifaceted debate (Schuklenk & Keinsmidt).   
There is yet another loophole with the initiation and follow up of VCT. 
Hypothetically, when a woman chooses to be tested and does find that her serostatus is 
positive, she may not adhere to partaking in the sometimes-available antiretroviral 
therapy (Bassett, 2002). This is due to the fact that ART regimens can be extremely 
burdensome. A devout commitment to keeping up with the disease is crucial for survival. 
Some patients with HIV have to take two to twenty pills at a time. The dedication 
required to taking the medication at specific time frames is meticulous for the individual. 
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Additionally, the side effects are often unpleasant. Another key piece of information that 
the patient has to be aware of is that certain other drugs, some of which are even over-
the-counter (OTC), taken in combination with HIV anti-retrovirals can produce some 
fatal side effects (Bradley-Springer, et al., 2007). These drawbacks discourage patients 
and put up barricades that keep them from being consistent with their treatment plans or 
successful in maintaining health and building immunity.  
Literature regarding the transmission of HIV mentions that MTCT can also be 
referred to as parent-to-child transmission (PTCT) because often the father of the child is 
responsible for infecting the mother in the first place. By interchanging the use of the 
abbreviation PTCT with MTCT, the mother is prevented from being solely disgraced or 
blamed for infecting her infant (Weinreich, 2003). The issue of the male’s role in this 
worldwide problem has so much to do with why these women become infected with HIV 
and then pass it on to their babies. The cycle just continues since it does not stop with the 
parents. Mother-to-child transmission could be significantly prevented if the males 
practiced morality and marital faithfulness to their spouses. There is a rampant inequality 
between the genders, and there has been for centuries in regards to female oppression, not 
in the feministic sense, but in relation to discrimination, lack of monetary resources, and 
forced sexual relations (Gross, 2004). The secretary-general of the United Nations, Kofi 
Annan, shared on International Women’s Day in March of 2004 that, “All over the world, 
women are increasingly bearing the brunt of the epidemic…because society’s inequalities 
put them at risk. There are many factors including poverty, abuse and violence, lack of 
information, coercion by older men, and men having several partners” (cited in Gross, p. 
1079). In that same year, Stephen Lewis, a United Nations diplomatic agent for 
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HIV/AIDS in Africa, alleged that AIDS coupled with unjust female oppression can serve 
as a death sentence to women on a worldwide scale. He attributed it to the male sexual 
behavior, the culture, the violence, the power, and the patriarchy, factors that have played 
an influential role for centuries (Gross).  
A study performed by Koenig, et al. discussed this issue of violence that happens 
during pregnancy to those women who may already have HIV or who are at risk for 
getting the virus. It supported that a number of factors influence an increase in the risk of 
violence particularly for women who are pregnant with HIV (2002). This could be 
attributed to location as well as dangerous behavior that can be associated with passing or 
acquiring HIV, which could include drug use, poor living or financial status, and sex 
bartering; all of which are factors that may welcome violence more easily (Koenig, et al., 
2002). If a pregnant woman is unaware of her HIV status and gets screened for it during a 
prenatal visit, it could be difficult to keep her positive serostatus a secret, which is 
another possible factor that brings violence upon the woman, when others find out she 
has contracted HIV (Koenig, et al., 2002). The study concluded and suggested that 
hundreds of pregnant women who are infected yearly with HIV are also affected by 
violence, and should be provided with counseling and screening by prenatal clinics or 
offices (Koenig, et al., 2002).  
A Focused Discussion on the Ugandan Experience  
A country in Africa that has been ravaged by violence through war and other 
means and has experienced HIV/AIDS in large quantities and is yet attempting to 
implement prevention strategies would be Uganda (Westerhaus, Finnegan, Zabulon, & 
Mukherjee, 2007). Reported from 1993, in Africa and the world, AIDS cases in Uganda 
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were in the lead for having the highest rates per population with 2,314/1,000,000 
population. One of the leading causes of death for Uganda has been HIV/AIDS with 2.4 
million people having HIV (Uganda Health Profile, 2001). The population of Uganda 
noted in 2005 was 28,816,000 people (Uganda, 2007). The research performed by 
Westerhaus, et al. focuses more specifically on Northern Uganda, which has been 
traumatized by violence; “political repression, economic inequality, and gender-based 
discrimination” are the very factors that eventually cause infants to get infected with HIV 
(p. 1184). Prevention must reach far beyond methods of abstinence, condom prevention, 
and behavior change because the issues entangled in the corruption of Northern Uganda 
involve a brutal competition between the Ugandan government and an insurgent group 
referred to as the Lord’s Resistance Army (LRA) (Westerhaus, et al.).  
Because of the vicious conflict between these two groups, children are abducted 
or forced to become “night commuters” where they run without parents or guardians for 
attempted safety during the night to hospitals or shelters, but along the way they may 
experience sexual assault that can lead to HIV. The boys abducted by the LRA are often 
forced to rape others as a war weapon and many of the girls become sex slaves as 
“wives” to the men of the army resulting in young children with HIV (Westerhaus, et al., 
2007). The probability of dying in Uganda under the age of five was recorded at 136 per 
1,000 live births in 2005 (Uganda, 2007). It is important to understand cases like this in 
which prevention attempts must stretch beyond traditional behavior change and 
awareness, and involve on a much deeper scale the social, political, and, economic 
resources of the world into strategies to prevent HIV from spreading further (Westerhaus, 
et al.).  
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The trials and blockades in Uganda that counteract progress on preventing HIV 
transmission continue to pervade. While attempts are being made at halting the violence 
that keeps HIV prevalent in war-torn Northern Uganda and finding appropriate 
prevention methods for slowing the HIV pandemic in Uganda, ethnographic research has 
been done on southeastern Uganda which poses that it is the husbands sexual indulgences 
outside of the marriage committment that causes the greatest risk for their wives to 
acquire the HIV infection (Parikh, 2007). If the ABC approach that stands for abstinence, 
be faithful, and the use of condoms is not taken seriously, which it clearly has not been, 
then HIV will continue to thrive (Parihk). The once-revered marital relationship that 
upheld trust, safety, and support is in some couples a cesspool for dishonesty, 
unfaithfulness, and greed. Now there is global evidence demonstrating that many women 
are at risk for getting infected with HIV from having sexual relations with their very own 
spouses or significant partners due to interactions that their men are having outside of the 
marriage commitment (Parihk). Even the marriage bed is no longer safe. The men need to 
take a stand and a responsibility to halt the virulent spread of this deadly disease that 
many helped cause themselves. If something is not done, they will watch their own nation 
vanish before them if AIDS does not take their lives first.  
Despite its alarming statistics, traumatic war experiences, and marital 
unfaithfulness, Uganda has been more recently recognized as a radical HIV success story 
in Africa in which HIV/AIDS cases have dramatically decreased (Parikh, 2007). What is 
ironic about this phenomena in Uganda is that people involved in assessing this case are 
facing great difficulty in answering the question “what worked” and having irrefutable 
evidence to demonstrate in the annals of Uganda where to attribute the success 
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(Parkhurst, 2008). They are having a hard time putting their finger on what has caused 
the decline. Thus, five components were instigated including HIV prevalence, HIV 
incidence, behavior change, causes of behavior change, and responsible policies in order 
to seek a viable explanation and foundational agreement for these more recent statistics 
(Parkhurst). These proponents of prevention represent a backwards cascade of cause and 
effect. For example, if the nation saw a change in behavior within the population, then 
what interventions or steps took place to reach that end result (Parkhurst)? Even so, there 
is a deficit in the data within the categories making it hard to establish where the country 
of Uganda succeeded and at what phase the most progress was made (Parkhurst). This 
information is extremely valuable as other nations are looking now to Uganda for 
answers so that they too can experience similar improvements within their country 
(Parkhurst). The following chart displays the numerical decline of HIV cases over the 
span of fourteen years in Uganda (Parkhurst). See Chart 3 below.  
 
 
 
 
 
 
 
 
Chart 3. Estimate Percentages of HIV Prevalence Decline in Uganda 1991-2005 
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Chart 3. Note: Information gathered to create Chart 3: Cited from Parkhurst, J.O. (2008). “What worked?” 
The evidence challenges in determining the causes of HIV prevalence decline. AIDS Education and 
Prevention, 20(3), 275-283.  
 
 These statistics demonstrate from different sources that the research is somewhat 
incongruent. For example, the data obtained from research done, shown in the first 
column between the years of 1992 and 1996, was gathered from a limited number of 
prenatal sites (Parkhurst, 2002). Also, it was written in the Science journal that there was 
a percentage peak of expecting mothers with HIV in Uganda in the year 1991 as shown 
above: 21.1%, but it significantly decreased seven years later to 9.7% (Stoneburner & 
Low-Beer, 2004). The 2004-2005 estimate documented in the Uganda Ministry of Health 
from 2006 recorded a national percentage of 6.4 from the sero-survey done, but UNAIDS 
estimated in 2004 that it was a percentage of 4.1 (UNAIDS, 2004b). Granted these 
“estimates” do show some inconsistency. Nonetheless, wherever the data is coming from, 
the bottom line is that the Ugandan percentage, as demonstrated in the chart above, has 
clearly been decreasing. 
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There is a deficit in data, yes, but not only are people working towards 
researching this issue; the plain fact is that HIV/AIDS has declined. It is news such as 
this that will keep the fetus, the infant, and the child from having to experience a life with 
HIV and AIDS. In certain cases the solution to the problem is simple, prevention. This 
does not belittle or down play that even in its short history, the HIV/AIDS pandemic has 
clearly ravaged and taken the lives of many people from nations and countries all over 
the world. Because of its deleterious effects and the wake-up call that it has brought to 
the world, many have been responsive to the cry for global assistance. Much has been 
done to halt its progression, however, a cure is not yet found. Because HIV is transmitted 
to infants through breastfeeding, pregnancy, and labor and delivery, research and clinical 
trials and rescue intervention must continue to be performed so that MTCT can be 
prevented in every way possible.  
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